Insiders who reported open-market trades in the last 12 months at the companies ORBIMED ADVISORS LLC files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
ORBIMED ADVISORS LLC is an investment firm, tracked as Director, 10% Owner of ADARx Pharmaceuticals, Inc. (ADRX). InsiderAlpha holds 44 primary Form 4 filings for it, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has ORBIMED ADVISORS LLC submitted recently?
5 primary Form 4 filings in the last 90 days, covering 5 companies.
Has ORBIMED ADVISORS LLC been buying or selling stock?
Recorded transactions: 33 open-market purchases ($159.07M) and 53 open-market sales ($154.99M) across all tracked filings.
ORBIMED ADVISORS LLC is Director, 10% Owner of ADARx Pharmaceuticals, Inc. (ADRX). 44 SEC Form 4 filings on record going back to 2024, most recently on 30 September 2026. Most recent open-market trade: bought $10.00M of ADRX on 30 September 2026. Lifetime open-market purchases: $159.07M. Lifetime open-market sales: $154.99M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by ORBIMED ADVISORS LLC.
InsiderAlpha's records for ORBIMED ADVISORS LLC go back to 2024: 44 primary Form 4 filings, an average of 14.7 per year. The typical open-market purchase is $7.23M (22 of 33 buys carry a usable dollar value, totaling $159.07M). The largest single buy on record is $30.00M of BRVE in 2026. Sales side: 53 recorded sales totaling $154.99M, so the filing history runs buy-heavy by dollar value. 20 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
